Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

Part of Germ cell tumors

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neuroendocrine Carcinoma

11 trials tracked for Neuroendocrine Carcinoma.

11Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 11
  1. Phase 2 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
  2. Phase 2 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed
  3. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  4. Phase 2 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed
  5. Phase 2 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Completed
  6. Phase 2 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed
Show 5 more trials
  1. Phase 2 TheraSphere for the Treatment of Liver Metastases Completed
  2. Phase 2 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma Completed
  3. Phase 2 Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors Completed
  4. Phase 2 Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Completed
  5. Phase 2 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial
Oncology RCT
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial New Combo Shows Modest Promise for Hard-to-Treat Neuroendocrine Cancers
This randomized phase II trial enrolled 185 patients with advanced neuroendocrine carcinoma refractory to platinum-based chemotherapy.
For patients with rare, aggressive neuroendocrine cancers that resist initial treatment, this study offers a new, though modest, combination…
Apr 23, 2026

Research across Germ cell tumors

Related studies from across the Germ cell tumors family.

Modified endoscopic mucosal resection offers comparable histologic efficacy to ESD for rectal neuroendocrine tumors
Gastroenterology Meta-analysis
Modified endoscopic mucosal resection offers comparable histologic efficacy to ESD for rectal neuroendocrine tumors Modified Endoscopic Mucosal Resection Shows Equal Results to ESD
This meta-analysis of 440 patients with rectal neuroendocrine tumors (r-NETs) $\leq$10 mm compares modified endoscopic mucosal resection (m-…
A new analysis shows modified endoscopic mucosal resection (m-EMR) provides similar results to ESD for rectal neuroendocrine tumors while be…
Oct 2, 2026
Narrative review offers practical recommendations for implementing PET-guided therapy workflows in clinical practice
Oncology Sys. Review
Narrative review offers practical recommendations for implementing PET-guided therapy workflows in clinical practice PET scans now guide your radiation treatment
This narrative review synthesizes evidence regarding the implementation of PET-guided therapy workflows.
Imagine standing in a doctor's office waiting for radiation therapy.
Frontiers Apr 23, 2026
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs
Oncology RCT
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs Adding a Drug Actually Hurted These Patients
A Phase II randomized controlled trial in 111 patients with advanced somatostatin receptor-positive GEP or bronchopulmonary NETs compared…
Adding a common chemotherapy drug to cancer treatment actually made tumors grow faster and reduced survival time for these patients.
Apr 16, 2026